Insurance coverage will be a challenge if not expanded to include other conditions, one physician said, so FDA approval is paramount. This challenge echoes concerns of patients, who also list high costs as the primary obstacle to GLP-1RA treatment, according to The Cure GLP-1RA Report: Insights from Patients on GLP-1RA Medications and the Future of Obesity Treatment, which reports results of a survey of patients who had taken GLP-1RA medications
It is a cys residue with acetylation and in this way it becomes a part of the cysteine pool in the cell to maintain the biosynthesis of GSH [6]
Diabetic polyneuropathy, neuropathies induced by certain medications, or alcohol-related neuropathy
They include the incretin effect, with the enhancement of insulin secretion by beta cells, improved insulin sensitivity, decrease in glucagon secretion, and reduced food intake due to induced satiety.11,45 The effect of this drug group on weight loss has had a worldwide impact due to its misuse through self-medication, and in turn, an increase in the number of cases of patients with adverse effects.12,4648 Approach to gastrointestinal symptoms in patients that are candidates for or receivers of antidiabetic treatment When evaluating patients with gastrointestinal symptoms that are going to start medical management for diabetes, it is important to ask if there are symptoms or diagnoses of functional dyspepsia, gastroparesis, intestinal bacterial overgrowth, irritable bowel syndrome, bloating, or chronic constipation, given that a large part of the therapeutic options can trigger or exacerbate symptomatology, such as early satiety, postprandial fullness, nausea, vomiting, bloating, diarrhea, and constipation.4951 In the case of patients that seek medical evaluation due to symptomatology that began after the start of pharmacologic management, the initial approach should focus on the symptoms and not associate them with the drugs as a first possibility, directly looking for alarm signs that merit endoscopy or colonoscopy.49 It is important to consider the drug group being utilized because different drugs among the different groups are associated with more symptoms than others, signifying that the molecule used can be modified, before suspending the drug group.5,42 Likewise, the initial dose and adequate drug titration should be evaluated, given that in some cases, adequate dose escalation of the drug can reduce or prevent gastrointestinal adverse effects, as occurs with the GLP-1 agonists.52 The temporality of the appearance of symptoms should be evaluated because in some cases the symptomatology tends to present in the first days of application
Rapid and irreversible inactivation of protein tyrosine phosphatases PTP1B, CD45, and LAR by peroxynitrite
